Shruti Bhandari

Shruti Bhandari

Auto-generated profile, based on publicly available information

Shruti Bhandari

Division of Hematology and Medical Oncology, James Graham Brown Cancer Center, University of Louisville, Louisville, KY

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2020 in Clinical Lung Cancer
Verified
Journal Article
Closed access
DPDanh Pham
Danh Pham
SBShruti Bhandari
Shruti Bhandari
CPChristina Pinkston
Christina Pinkston
MOMalgorzata Oechsli
Malgorzata Oechsli
GKGoetz Kloecker
Goetz Kloecker

20 May 2018 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
DPDanh Pham
Danh Pham
SBShruti Bhandari
Shruti Bhandari
MOMalgorzata Oechsli
Malgorzata Oechsli
CPChristina M Pinkston
Christina M Pinkston
GKGoetz H. Kloecker
Goetz H. Kloecker
6504Background: Lung cancer is the leading cause of cancer related mortality in the United States. Since 2013, the United States Preventive Services Task Force (USPSTF) recommended annual screening for lung cancer with low-dose computed tomography (LDCT) for those aged 55-80 years for those who have smoked at least 30 pack years who currently smoke or have quit within the past 15 years. Current literature has provided only estimates of lung cancer screening since implementation. Our study aims to present the number of screening LDCTs being performed across the United States. Methods: Using data from the Lung Cancer Screening Registry (LCSR) provided by the American College of Radiology (ACR) in 2016, we collected the total number of LDCT from all 1,796 accredited radiographic screening sites. We used the 2015 National Health Interview Survey (NHIS) to estimate screening eligible smokers per USPSTF criteria and compared them with the 2016 LCSR reported screens. Analyses excluded respondents with missing da...

1 August 2018 in Seminars in Oncology
Verified
Journal Article
Closed access
SBShruti Bhandari
Shruti Bhandari
AGAmitoj S Gill
Amitoj S Gill
CPCesar A Perez
Cesar A Perez
DJDharamvir Jain
Dharamvir Jain

1 October 2018 in American Journal of Clinical Oncology
Verified
Journal Article
Closed access
AGAmitoj Gill
Amitoj Gill
RGRohit Gosain
Rohit Gosain
SBShruti Bhandari
Shruti Bhandari
RGRahul Gosain
Rahul Gosain
GGGurkirat Mbbs Gill
Gurkirat Mbbs Gill
KMKenneth Miller
Kenneth Miller
Background: Follow-up cancer care is important for patients who have received IV chemotherapy but some patients discontinue their care and are lost to follow-up (LFU) at the cancer center where they were treated. The purpose of this study was to determine what proportion of cancer survivors are LFU at 5 years after treatment, the timing of LFU, and the characteristics of those who do not continue survivorship care. Methods: Adult patients with cancer who were treated with chemotherapy at a large community teaching hospital in 2006 and 2007 were identified and linked with State tumor registry data. Hospital medical records were reviewed to obtain information on demographics, diagnosis, treatment, and date of last follow-up visit. Characteristics of patients with ≥5 years of follow-up care were compared with those who were LFU. Results: In total, 487 patients received chemotherapy and 304 died (62%) during the 5-year follow-up period. Among the 183 cancer patients who were known to be alive at 5 years, 92 (50%) were LFU and 50% (46/92) of this LFU group were LFU within 1 year of diagnosis. At 5 years, follow-up care was continuing for 55% of women, compared with 39% of men. The highest proportion of follow-up was observed among lung cancer patients (84%), followed by patients with breast cancers (63%) and gastrointestinal cancers (40%). Patients with hematological cancers had the lowest follow-up proportion at 5 years (29%) (P<0.05). Follow-up was not significantly associated with age (P=0.48), insurance status(P=0.29), and race(P=0.06). Conclusions: It is estimated that 65% of the cancer survivors in the United States are ≥5 years beyond their diagnosis but there is little data on oncology follow-up rates. In our retrospective study of 183 patients who were treated with chemotherapy only 49.7% continue to follow-up at their treatment center. LFU has important implications in planning long-term care strategies for cancer survivors and in survivorship research.

16 September 2019 in Medical Oncology
Verified
Journal Article
Closed access
PDF file
SBShruti Bhandari
Shruti Bhandari
RKRohit Kumar
Rohit Kumar
PTPrashant Tripathi
Prashant Tripathi
ACAbigail Chan
Abigail Chan
SMSarah Mudra
Sarah Mudra
RRRebecca Redman
Rebecca Redman

1 April 2020 in Current Problems in Cancer
Verified
Journal Article
Closed access
RKRohit Kumar
Rohit Kumar
SBShruti Bhandari
Shruti Bhandari